SRINIVAS NERELLA

Dr. SRINIVAS NERELLA

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SKShravankumar Kankala
Shravankumar Kankala
Ranjith KankalaRanjith Kankala
Ranjith Kankala
PGPrasad Gundepaka
Prasad Gundepaka
NTNiranjan Thota
Niranjan Thota
SRINIVAS NERELLASRINIVAS NERELLA
SRINIVAS NERELLA
CVChandra Sekhar Vasam
Chandra Sekhar Vasam

2 October 2013 in RSC Advances
Verified
Journal Article
Closed access
PDF file
SKShravankumar Kankala
Shravankumar Kankala
SRINIVAS NERELLASRINIVAS NERELLA
SRINIVAS NERELLA
RVRavinder Vadde
Ravinder Vadde
CVChandra Sekhar Vasam
Chandra Sekhar Vasam
An efficient and green procedure for the synthesis of Markovnikov i.e. branched vinyl sulfides in aqueous media was developed by employing the dinuclear Rh(I) complexes of hydrophilic phosphines as catalysts in the alkyne hydrothiolation with aliphatic thiols. Deuterium-labeling studies provide evidence for the aptness of these dinuclear catalysts to form selectively the Markovnikov syn-addition products. Catalyst order experiments disclose that the order with respect to the concentration of the catalyst is one, i.e. in solution the active catalyst is dinuclear with one active metal center and the second metal center contribute the cooperative effects to influence the Markovnikov selectivity in hydrothiolation. Further, the possibility of catalyst recovery and recycling experiments were also demonstrated.

1 June 2022 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
SPSuresh Paidakula
Suresh Paidakula
SRINIVAS NERELLASRINIVAS NERELLA
SRINIVAS NERELLA
SKShravankumar Kankala
Shravankumar Kankala
Ranjith KankalaRanjith Kankala
Ranjith Kankala
: Although significant progress over several decades has been evidenced in cancer therapy, there remains a need for the development of novel and effective therapeutic strategies to treat several relapsed and intractable cancers. In this regard, tubulin protein has become one of the efficient and major targets for anticancer drug discovery. Considering the antimitotic ability, several tubulin inhibitors have been developed to act against various cancers. Among various tubulin inhibitors available, combretastatin-A4 (CA-4), a naturally occurring lead molecule, offers exceptional cytotoxicity (including the drugresistant cell lines) and antivascular effects. Although CA-4 offers exceptional therapeutic efficacy, several new advancements have been proposed, in terms of structural modification via A and B rings, as well as cis-olefinic bridging, which provide highly efficient analogs with improved tubulin-binding efficiency to meet the anticancer drug development requirements. This review systematically emphasizes the recent trends and latest developments in the anticancer drug design and discovery using CA-4 analogs as the tubulin inhibiting agents by highlighting their structure-activity relationships (SAR) and resultant pharmacological efficacies.

1 August 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SPSuresh Paidakula
Suresh Paidakula
SRINIVAS NERELLASRINIVAS NERELLA
SRINIVAS NERELLA
RVRavinder Vadde
Ravinder Vadde
AKAhmed Kamal
Ahmed Kamal
SKShravankumar Kankala
Shravankumar Kankala

18 June 2019 in Natural Product Research
Verified
Journal Article
Closed access
SRINIVAS NERELLASRINIVAS NERELLA
SRINIVAS NERELLA
SKShravankumar Kankala
Shravankumar Kankala
BGBrahmeshwari Gavaji
Brahmeshwari Gavaji
Herein we report the regioselective synthesis of podophyllotoxin-Glycosyl triazole hybrids catalysed by Ag(I)-N-heterocyclic carbene (Ag(I)-NHC) in a short reaction time (∼30 min) at ambient conditions. In principle, it is the first report of Click alkyne-azide cycloaddition catalysed by Ag(I)-NHC catalyst and moreover, this new methodology yielded good results when compared with traditional CuAAC in terms of reaction time and selectivity. The synthesised compounds were further explored for in vitro anticancer activity against four human cancer cell lines Du145, HeLa, A-549, and MCF-7 and found that these synthesised compounds possess significant anticancer activity. Further, the compounds 5a and 5e were identified as promising leads due to their better activity across all cell lines than that of the standard drug etoposide. Molecular docking studies of 5a & 5e with DNA Topoisomerase-II were revealed that the free energy calculations of active compounds were in good agreement with observed IC50 values.

1 January 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SRINIVAS NERELLASRINIVAS NERELLA
SRINIVAS NERELLA
SKShravankumar Kankala
Shravankumar Kankala
SPSuresh Paidakula
Suresh Paidakula
BGBrahmeshwari Gavaji
Brahmeshwari Gavaji